![]() On Thursday, Judge Breyer further whittled down the list of defendants. District Judge Charles Breyer dismissed the racketeering claims, but allowed the public nuisance claims to go through. ![]() The city's suit made a number of what were at the time novel allegations, including public nuisance and racketeering. But some parties remain, including Walgreens, Actavis, Teva Pharmaceuticals and Endo Pharmaceuticals, the latter two of which specialize in making generic versions of drugs. Some of those defendants, like Purdue, have been released from the case thanks to settlements. San Francisco filed its suit in 2018 against a panoply of defendants, including Purdue, nine members of the Sackler family and a host of other companies. The drugmaker Johnson & Johnson and three pharmaceutical distributors agreed to a $26 billion settlement with states and municipalities in February.īut that still leaves a multitude of other opioid-related lawsuits in active litigation. The former owners of the company, the Sackler family, contributed $6 billion to the settlement, a good deal of which went to the governmental entities, in exchange for immunity from future lawsuits. That proceeding hit the pause button on all lawsuits against Purdue, and eventually lead to a massive settlement, in which cities and states will effectively take over ownership of Purdue. The biggest culprit was Purdue Pharma, which manufactured and marketed Oxycontin, and which entered bankruptcy in 2020. According to the CDC, nearly half a million people died from opiate overdoses between 19. Many patients who were prescribed an opiate later switched over to using illegal narcotics like heroin. Thousands of states, cities and counties have sued pharmaceutical companies over their role in the opioid epidemic, which is believed to have been caused by the marketing and overprescription of prescription drugs like Oxycontin. (CN) - A federal judge on Thursday cleared the way for San Francisco's opioid lawsuit against Walgreens and a number of pharmaceutical companies to head to trial, which is set to begin on April 25.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |